HR job title
- Associate Professor
- Contact Info
- Websites
- ORCiD
- 0000-0003-2048-122X
Zhong, Lixian Assistant Professor
Positions
- Assistant Professor, Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy
is an Assistant Professor of Rangel College of Pharmacy. Her research interest lies at the intersection of science, medicine and economics to assess clinical, economic and humanistic values of medical interventions and she conducts research on the costs and outcomes associated with pharmaceutical products.
She has conducted research using clinical trial data, real world data, large survey data and economic modeling to study cost-effectiveness of new interventions for cancer and neurological diseases. Since joining Texas A&M University as an assistant professor at the College of Pharmacy in 2015, she is conducting research in: evaluating utilization, costs and outcomes associated with medications and other health care services in patients with chronic diseases, health disparity, cost-effectiveness of new interventions, drug pricing and reimbursement.
She holds a Ph.D in Pharmacology and an M.A. in Economics from Duke University. She completed her post-doctoral fellowship training in Pharmacoeconomics and Outcomes research from University of California, San Francisco. She has conducted research in academic, international organization and industry settings.
She has conducted research using clinical trial data, real world data, large survey data and economic modeling to study cost-effectiveness of new interventions for cancer and neurological diseases. Since joining Texas A&M University as an assistant professor at the College of Pharmacy in 2015, she is conducting research in: evaluating utilization, costs and outcomes associated with medications and other health care services in patients with chronic diseases, health disparity, cost-effectiveness of new interventions, drug pricing and reimbursement.
She holds a Ph.D in Pharmacology and an M.A. in Economics from Duke University. She completed her post-doctoral fellowship training in Pharmacoeconomics and Outcomes research from University of California, San Francisco. She has conducted research in academic, international organization and industry settings.
- Overview
- Publications
- Teaching
- Background
- Contact
- Other
- View All
Overview
Publications
selected publications
-
academic article
-
Lin, D., Luo, S., Lin, S., Zhong, L., Zhou, W., Gu, D., ... Weng, X.
(2023).
Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis. 21(1), 8-15.
-
Lin, S., Lin, D., Li, Y., Zhong, L., Zhou, W., Wu, Y., ... Weng, X.
(2023).
Disease burden of prostate cancer from 2014 to 2019 in the United States: estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey. Epidemiology and Health.
45, e2023038-e2023038.
-
Berrios, K., Burum, A., Jeong, E., & Zhong, L.
(2022).
Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis. Journal of Managed Care & Specialty Pharmacy.
28(11), 1282-1291.
-
Ory, M. G., Lee, S., Dahlke, D. V., Pardo, N., Zhong, L., McCord, C. E., Alonzo, J. P., & Smith, M. L.
(2022).
Physicians' interest in different strategies for supporting pain -management and opioid prescribing: A cross-sectional study. Journal of Opioid Management: a medical journal of proper and adequate use.
18(6), 511-521.
-
Ionova, Y., Zhong, L., Ma, Y., & Wilson, L.
(2022).
CO31 Health Equity Considerations in Minority Groups with Type 1 and 2 Diabetes in the COVID-19 Era: Care Utilizations and Costs. 25(7), s310-S310.
-
Chan, A., Dang, C., Wisniewski, J., Weng, X., Hynson, E., Zhong, L., & Wilson, L.
(2022).
A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology: cancer clinical trials.
45(2), 66-73.
-
Chen, Y., Wu, L., J Hernndez-Muoz, J., J Miller, M., Pope, M., Huyan, Y., & Zhong, L.
(2022).
The economic burden of systemic sclerosis-A systematic review. International Journal of Rheumatic Diseases.
25(2), 110-120.
-
Ionova, Y., Vuong, W., Sandoval, O., Fong, J., Vu, V., Zhong, L., & Wilson, L.
(2022).
Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA. Clinical Drug Investigation.
42(6), 491-500.
-
Weng, X., Zhong, L., Xiang, P., Li, Y., Paciorek, A., Dong, L., ... Wilson, L.
(2022).
Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence. European Journal of Cancer Care.
31(6), e13740.
-
Berrios, K., Burum, A., Jeong, E., & Zhong, L.
(2022).
EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis. Value in Health.
25(7), s425-S425.
-
Dong, L., Lin, S., Zhong, L., Nian, D., Li, Y., Wang, R., ... Xu, X.
(2022).
Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis. Clinical Breast Cancer.
22(1), e21-e29.
-
Tran, A. T., Rizk, E., Haas, E. M., Naufal, G., Zhong, L., & Swan, J. T.
(2022).
Real-World Data on Liposomal Bupivacaine and Inpatient Hospital Costs After Colorectal Surgery. Journal of Surgical Research.
272, 175-183.
-
Hernndez-Muoz, J. J., Kamdar, C. R., Zhong, L., Alonzo, J., & Sprenger, L.
(2021).
Impact of a pharmaceutical care incentive program on the asthma medication ratio among pediatric patients with persistent asthma enrolled in a Medicaid program. Journal of Managed Care & Specialty Pharmacy.
27(6), 714-723.
-
Dong, L., Nian, D., Huang, Y., Lin, S., Zhong, L., & Xu, X.
(2021).
HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis. Value in Health.
24, s9-S9.
-
Li, Y., Lin, S., Zhong, L., Luo, S., Huang, X., Huang, X., ... Weng, X.
(2021).
Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?. Pharmacogenomics.
22(13), 809-819.
-
Tran, A. T., Rizk, E., Haas, E. M., Naufal, G., Zhong, L., & Swan, J. T.
(2021).
PSU5 Liposomal Bupivacaine and Inpatient Hospital Costs after Colorectal Surgery. Value in Health.
24, s224-S224.
-
Jeong, E., Wang, C., Wilson, L., & Zhong, L.
(2021).
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women. 11, 658054.
-
Weng, X., Luo, S., Lin, S., Zhong, L., Li, M., Xin, R., Huang, P., & Xu, X.
(2020).
Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels. 28(2), 117-125.
-
Lin, S., Luo, S., Zhong, L., Lai, S., Zeng, D., Rao, X., Huang, P., & Weng, X.
(2020).
Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. 42(4), 1175-1183.
-
Zhong, L., Pope, M., Shen, Y. e., Hernandez, J. J., & Wu, L.
(2019).
Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. International Journal of Rheumatic Diseases.
22(12), 2096-2107.
-
Tang, J., Zhong, L., Paoli, C., Paciorek, A., Carroll, P., & Wilson, L.
(2019).
Longitudinal Comparison of Patient-Level Outcomes and Costs Across Prostate Cancer Treatments With Urinary Problems. American Journal of Men's Health.
13(2), 1557988319835326-155798831983532.
-
Wu, L., & Zhong, L.
(2019).
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of Medical Economics.
22(2), 187-195.
-
Zhong, L., Tran, A. T., Tomasino, T., Nugent, E., & Smith, J. A.
(2018).
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of Managed Care & Specialty Pharmacy.
24(12), 1219-1228.
-
Wilson, L. S., Loucks, A., Gipson, G., Zhong, L., Bui, C., Miller, E., ... McCulloch, C. E.
(2015).
Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies. International Journal of MS Care.
17(2), 74-82.
-
Wilson, L., Tang, J., Zhong, L., Balani, G., Gipson, G., Xiang, P., Yu, D., & Srinivas, S.
(2014).
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?. Journal of Oncology Pharmacy Practice.
20(6), 417-425.
-
Wilson, L., Loucks, A., Bui, C., Gipson, G., Zhong, L., Schwartzburg, A., ... McCulloch, C.
(2014).
Patient centered decision making: Use of conjoint analysis to determine riskbenefit trade-offs for preference sensitive treatment choices. Journal of the Neurological Sciences.
344(1-2), 80-87.
-
Wilson, L. S., Loucks, A., Bui, C. T., Gipson, G., Zhong, L., Tang, J., ... McCulloch, C. E.
(2013).
PND37 Patient preferences for attributes of disease modifying Therapies: Results of a choice based conjoint analysis. Value in Health.
16(3), a107-A107.
-
Wilson, L. S., Zhong, L., Pon, V., Srinivas, S., Frear, M., Nguyen, N., ... Loucks, A.
(2012).
PCN72 Cost Effectiveness Analysis of New Treatments for Metastatic Castration-Resistant Prostate Cancer: Does Severity Matter?. Value in Health.
15(4), a220-a221.
-
Lee-Grossman, C. W., Saunders, W. B., Wilson, L. S., & Zhong, L.
(2012).
PND3 The Population-Based Impact of MS in Asia. Value in Health.
15(7), a675-A675.
-
Zhong, L., Srinivas, S., Pon, V., Nguyen, N., Frear, M., Kwan, S., ... Wilson, L.
(2012).
Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis. Journal of Clinical Oncology.
30(15_suppl), e15154-e15154.
-
Zhong, L., Bellemer, A., Yan, H., Ken, H., Jessica, R., Hwang, R. Y., Pitt, G. S., & Tracey, W. D.
(2012).
Thermosensory and Nonthermosensory Isoforms of Drosophila melanogaster TRPA1 Reveal Heat-Sensor Domains of a ThermoTRP Channel. Cell Reports.
1(1), 43-55.
-
Zhong, L., Hwang, R. Y., & Tracey, W. D.
(2010).
Pickpocket Is a DEG/ENaC Protein Required for Mechanical Nociception in Drosophila Larvae. Current Biology.
20(5), 429-434.
-
Hwang, R. Y., Zhong, L., Xu, Y., Johnson, T., Zhang, F., Deisseroth, K., & Tracey, W. D.
(2007).
Nociceptive Neurons Protect Drosophila Larvae from Parasitoid Wasps. Current Biology.
17(24), 2183-2183.
-
Schwartz, N. U., Zhong, L., Bellemer, A., & Tracey, W. D.
Egg Laying Decisions in Drosophila Are Consistent with Foraging Costs of Larval Progeny. PLoS ONE.
7(5), e37910-e37910.
-
Zhong, L., Pon, V., Srinivas, S., Nguyen, N., Frear, M., Kwon, S., ... Wilson, L.
Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis. PLoS ONE.
8(5), e64275-e64275.
-
Lin, D., Luo, S., Lin, S., Zhong, L., Zhou, W., Gu, D., ... Weng, X.
(2023).
Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis. 21(1), 8-15.
-
conference paper
-
Ionova, Y., Zhong, L., Ma, Y., & Wilson, L.
(2022).
HEALTH EQUITY CONSIDERATIONS IN MINORITY GROUPS WITH TYPE 1 AND 2 DIABETES IN THE COVID-19 ERA: CARE UTILIZATIONS AND COSTS. Value in Health.
S310-S310.
-
Berrios, K., Burum, A., Jeong, E., & Zhong, L.
(2022).
IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS. Value in Health.
S425-S425.
-
Berrios, K., Burum, A., Jeong, E., & Zhong, L.
(2022).
IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS. Value in Health.
S425-S425.
-
Dong, L., Nian, D., Huang, Y., Lin, S., Zhong, L., & Xu, X.
(2021).
EVALUATION OF TUCATINIB FOR HER2-POSITIVE BREAST CANCER PATIENTS WITH BRAIN METASTASES: A UNITED STATES-BASED COST-EFFECTIVENESS ANALYSIS. Value in Health.
S9-S9.
-
Tran, A. T., Rizk, E., Haas, E. M., Naufal, G., Zhong, L., & Swan, J. T.
(2021).
LIPOSOMAL BUPIVACAINE AND INPATIENT HOSPITAL COSTS AFTER COLORECTAL SURGERY. Value in Health.
S224-S224.
-
Dawamne, T., & Zhong, L.
(2021).
NEONATAL ABSTINENCE SYNDROME INCIDENCE RATE, CLINICAL CHARACTERISTICS & HEALTHCARE RESOURCE UTILIZATION IN TEXAS DURING 2006-2017. Value in Health.
S91-S91.
-
Jeong, E., Tomasino, T., Sprenger, L., Alonzo, J., Zhong, L., & Hernandez, J.
(2020).
Meeting Abstracts - AMCP 2020 - Effect of an Asthma-Related Educational Intervention Targeting Pharmacies in a Managed Care Organization CHIP/Medicaid Network in the Provision of Pharmaceutical Care Incentive Programs for Asthma and Patients' Process and Outcomes Measures. Journal of Managed Care & Specialty Pharmacy.
S1-S96.
-
Jeong, E., Nguyen, V., Ngo, H., Gu, D., & Zhong, L.
(2020).
COST-EFFECTIVENESS OF RIBOCICLIB PLUS ENDOCRINE THERAPY IN TREATING PREMENOPAUSAL OR PERIMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN THE UNITED STATES. Value in Health.
S70-S70.
-
Wu, L., & Zhong, L.
(2018).
BUDGET IMPACT ANALYSIS OF NIRAPARIB AND OLAPARUB AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE, RECURRENT OVARIAN CANCER IN THE US. Value in Health.
S22-S22.
-
Zhong, L., Tran, A. T., Tomasino, T., Smith, J. A., & Nugent, E. K.
(2018).
COST-EFFECTIVENESS OF NIRAPARIB AND OLAPARIB AS MAINTENANCE THERAPY FOR PATIENTS WITH PLATINUM SENSITIVE < RECURRENT OVARIAN CANCER. Value in Health.
S29-S29.
-
Zhong, L., Pope, M., & Wu, L.
(2017).
EPIDEMIOLOGY AND ECONOMIC BURDEN OF SYSTEMIC SCLEROSIS - A SYSTEMATIC REVIEW. Value in Health.
A217-A217.
-
Zhong, L., Douglas, C., Hutchison, R., & Potter, D.
(2016).
UTILIZATION PATTERN OF PRESCRIPTION PAIN MEDICATION AMONG ADULTS WITH DIABETES MELLITUS. Value in Health.
A204-A204.
-
Ionova, Y., Zhong, L., Ma, Y., & Wilson, L.
(2022).
HEALTH EQUITY CONSIDERATIONS IN MINORITY GROUPS WITH TYPE 1 AND 2 DIABETES IN THE COVID-19 ERA: CARE UTILIZATIONS AND COSTS. Value in Health.
S310-S310.
-
institutional repository document
-
Li, Y., Lin, S., Lin, D., Zhong, L., Wu, Y., Xie, C., ... Weng, X.
(2022).
Disease Burden of Prostate Cancer from 2014 to 2019: Estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey
-
Li, Y., Lin, S., Lin, D., Zhong, L., Wu, Y., Xie, C., ... Weng, X.
(2022).
Disease Burden of Prostate Cancer from 2014 to 2019: Estimation from the Global Burden of Disease Study 2019 and Medical Expenditure Panel Survey
Teaching
teaching activities
- PHAR628 Research Methods/biostatics Instructor
- PHAR658 Pub Health & Pharmacoepi Instructor
- PHAR757 Pharmacy Mgmt And Pharmecon Instructor
- PHAR785 Independent Study Instructor
- PHAR789 Sptp: Research Track Ii Instructor
- PHAR856 Pharmacoeconomics Instructor
- PHSC621 Biostatistics Instructor
- PHSC685 Directed Studies Instructor
- PHSC691 Research Instructor
Background
education and training
- Ph.D. in Pharmacology, Duke University - (Durham, North Carolina, United States) 2011
- M.A. in Economics, Duke University - (Durham, North Carolina, United States) 2010
- B.S. in Biological Sciences, Peking University - (Beijing, Beijing, China) 2003
Contact
first name
- Lixian
has last name
- Zhong
Other
- zhong@tamu.edu